Progyny Stock
Progyny, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Country
- United States
- CEO
- Pete Anevski
- Employees
- 846
- Market cap
- $2.1 B
- IPO
- 25/10/2019
Progyny, Inc. functions as a benefits management corporation within the Healthcare sector. Headquartered in New York City, USA, the company is listed on the NASDAQ and operates in the Medical - Healthcare Plans industry. The core business model focuses on providing specialized solutions for fertility and broader…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Progyny stock: price history
1D
-2.2%
1W
-3.8%
1M
-1.9%
6M
+48.2%
YTD
+4.6%
1Y
+25.9%
2Y
+62.1%
5Y
-52.0%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~89% stronger price swings than usual
Ask the agents about Progyny
Analyst assessment of Progyny
PRICE TARGET LOW
US$30.00
CONSENSUS
US$35.50
MEDIAN
US$35.50
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
14
BUY
6
HOLD
0
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 08/09/2026
Progyny stock metrics
P/E
27.69
P/B
4.63
EV/EBITDA
15.23
RETURN ON EQUITY
6.2%
NET MARGIN
8.0%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.5%
FLOAT SHARES
70,228,805
AVG. DAILY VOLUME (30D)
1,187,050
Insider transactions (SEC)
Cummings Melissa B
Cummings Melissa B
Swartz Allison
Clapp Geoffrey
GORDON KEVIN K
Institutional holders
Comparable stocks
Frequently asked questions about Progyny stock
What does Progyny do?
Progyny, Inc. is a company in the Healthcare sector, Medical - Healthcare Plans industry, headquartered in United States.
The CEO is Pete Anevski, the company employs around 846 people.
The IPO was on 25/10/2019; the stock trades on NASDAQ under the ticker PGNY.
What do analysts say about Progyny stock?
20 analysts rate the stock, the consensus is Buy (as of 08/09/2026).
The average price target is US$35.50, ranging from US$30.00 to US$40.00, with a median of US$35.50.
This is an external assessment, not a statement by Market Jury.
When does Progyny report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 89% stronger than usual.
Does Progyny pay a dividend?
No, Progyny currently does not pay a dividend.
Which stocks are comparable to Progyny?
Comparable stocks include UnitedHealth Group, CVS Health, Elevance Health, Cigna, Humana, Centene, Molina Healthcare and Oscar Health.
How can I get Progyny stock analyzed?
Clicking "Analyze stock" lets five strategies assess Progyny against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.